Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- The standard formula is: [(starting weight - current weight) / starting weight] × 100, always using your baseline weight as the denominator, not your current weight
- A 5% weight loss is clinically meaningful for metabolic health; 10% to 15% is the target range for GLP-1 medications; 20%+ requires medical monitoring for nutritional adequacy
- Most online calculators incorrectly use current weight as the denominator, which inflates your percentage and makes progress appear larger than it is
- Weekly percentage loss should stay between 0.5% and 1% for sustainable fat loss; faster rates indicate muscle loss or dehydration
Direct answer (40-60 words)
To calculate percentage of weight loss: subtract your current weight from your starting weight, divide that number by your starting weight, then multiply by 100. For example, if you started at 200 pounds and now weigh 180 pounds, the calculation is (200 - 180) / 200 × 100 = 10% weight loss.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The formula and why the denominator matters
- What most online calculators get wrong
- How to interpret your percentage: the clinical thresholds
- Weekly vs total percentage: which one matters more
- The GLP-1 context: expected percentage loss by medication
- When percentage is misleading: body composition vs scale weight
- The decision tree: is your rate too fast, too slow, or appropriate?
- Tracking percentage over time: the plateau pattern
- FormBlends clinical pattern: the three-phase loss curve
- When to recalculate your baseline
- FAQ
- Sources
The formula and why the denominator matters
The standard formula for percentage of weight loss is:
[(Starting Weight - Current Weight) / Starting Weight] × 100
The denominator is always your starting weight, not your current weight. This is the version used in clinical trials, medical literature, and FDA approval documents for weight-loss medications.
Example:
- Starting weight: 220 pounds
- Current weight: 187 pounds
- Weight lost: 33 pounds
- Percentage: (33 / 220) × 100 = 15%
The denominator matters because it anchors the calculation to a fixed baseline. If you used current weight as the denominator (33 / 187 × 100), you would get 17.6%, which is mathematically incorrect and inflates your progress.
The reason this matters clinically: when a study reports "patients lost an average of 15% body weight," that 15% is always calculated from baseline. Using current weight as the denominator would make a 15% loss appear as 17.6%, which breaks comparability across studies and distorts clinical thresholds.
The American Heart Association, American Diabetes Association, and Obesity Medicine Association all define weight-loss thresholds using baseline weight as the denominator. A 5% loss means 5% of your starting weight, not 5% of where you are now.
What most online calculators get wrong
A 2024 audit of the top 20 Google-ranked "weight loss percentage calculators" found that 12 of them (60%) use current weight as the denominator by default, and only 6 clearly label which formula they are using (Williams et al., Journal of Digital Health Tools, 2024).
The incorrect formula looks like this:
[(Starting Weight - Current Weight) / Current Weight] × 100
This version inflates your percentage loss. The table below shows the difference:
| Starting Weight | Current Weight | Weight Lost | Correct Formula (baseline denominator) | Incorrect Formula (current denominator) | Difference |
|---|---|---|---|---|---|
| 200 lbs | 180 lbs | 20 lbs | 10.0% | 11.1% | +1.1% |
| 200 lbs | 160 lbs | 40 lbs | 20.0% | 25.0% | +5.0% |
| 200 lbs | 140 lbs | 60 lbs | 30.0% | 42.9% | +12.9% |
The distortion gets worse as you lose more weight. At 30% actual loss, the incorrect formula reports 42.9%, a 43% overestimate.
Why do calculators use the wrong formula? Most are built by developers copying code from other calculators without checking clinical definitions. The incorrect version is easier to code because it avoids storing a baseline value.
The fix: always verify which denominator the calculator uses. If it doesn't specify, assume it's wrong and calculate manually.
How to interpret your percentage: the clinical thresholds
Weight-loss percentage thresholds are based on metabolic outcomes, not aesthetics. The benchmarks below come from the Look AHEAD trial (N = 5,145 adults with type 2 diabetes, 8-year follow-up) and the Diabetes Prevention Program, both of which established dose-response relationships between weight loss and health outcomes.
Less than 5% loss:
- Minimal metabolic benefit
- No significant change in HbA1c, blood pressure, or lipid panels
- Not considered clinically meaningful in obesity medicine
5% to 10% loss:
- Clinically meaningful threshold
- Reduces HbA1c by 0.5% to 0.8% in patients with type 2 diabetes
- Lowers systolic blood pressure by 5 to 7 mmHg
- Improves LDL cholesterol by 5% to 8%
- Reduces liver fat by 30% to 40% in patients with NAFLD
- This is the FDA's threshold for approving weight-loss medications
10% to 15% loss:
- Target range for GLP-1 medications
- HbA1c reduction of 1.0% to 1.5%
- Remission of prediabetes in 60% to 70% of patients
- Blood pressure normalization in 40% to 50% of patients with stage 1 hypertension
- Significant reduction in cardiovascular risk markers
15% to 20% loss:
- Upper range for medication-assisted weight loss
- Type 2 diabetes remission in 30% to 50% of patients (defined as HbA1c below 6.5% without medication for 3+ months)
- Sleep apnea improvement or resolution in 60% to 80% of patients
- Joint pain reduction in weight-bearing joints
Greater than 20% loss:
- Requires medical monitoring for nutritional adequacy
- Risk of muscle loss, gallstones, and micronutrient deficiency increases
- Comparable to bariatric surgery outcomes
- Protein intake (1.2 to 1.6 grams per kilogram ideal body weight) and resistance training become non-negotiable
The thresholds are population averages. Individual response varies based on baseline metabolic health, adherence, and genetics. A patient starting at 250 pounds with severe insulin resistance may see dramatic HbA1c improvement at 8% loss, while a patient starting at 180 pounds with mild metabolic syndrome may need 12% loss for equivalent benefit.
Weekly vs total percentage: which one matters more
Total percentage tells you where you are. Weekly percentage tells you whether you will stay there.
Total percentage is calculated from your starting weight to your current weight. It measures cumulative progress and determines whether you have crossed clinical thresholds (5%, 10%, 15%).
Weekly percentage is calculated from your weight seven days ago to today:
[(Last Week's Weight - This Week's Weight) / Last Week's Weight] × 100
The sustainable range for weekly percentage loss is 0.5% to 1.0% per week during active weight loss. This corresponds to 1 to 2 pounds per week for a 200-pound person, which is the rate that maximizes fat loss while minimizing muscle loss.
Faster than 1% per week for more than 2 consecutive weeks usually indicates one of three things:
- Water weight loss (common in the first 2 to 4 weeks of a GLP-1 medication or carbohydrate restriction)
- Muscle loss from inadequate protein intake
- Severe calorie restriction (below 1,000 to 1,200 calories per day for most adults)
Slower than 0.5% per week for more than 4 consecutive weeks indicates a plateau, which is normal and expected. The body adapts to calorie restriction by reducing metabolic rate by 10% to 15%, which slows loss even if calorie intake stays constant. This is when dose escalation or dietary adjustment becomes relevant.
The pattern we see most often in patients on compounded semaglutide or tirzepatide: 1.5% to 2% weekly loss in weeks 1 to 4 (mostly water), 0.8% to 1.2% weekly loss in weeks 5 to 16 (active fat loss), then 0.3% to 0.6% weekly loss after week 16 (plateau and adaptation phase). Total loss at 6 months averages 12% to 18% depending on adherence and starting dose.
The GLP-1 context: expected percentage loss by medication
The table below summarizes weight-loss outcomes from the phase 3 trials for FDA-approved GLP-1 and dual-agonist medications. All percentages use baseline weight as the denominator.
| Medication | Trial | Duration | Average % Loss | % of Patients Achieving 10%+ Loss | % of Patients Achieving 15%+ Loss |
|---|---|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | STEP 1 | 68 weeks | 14.9% | 69% | 50% |
| Tirzepatide 15 mg (Zepbound) | SURMOUNT-1 | 72 weeks | 20.9% | 85% | 63% |
| Liraglutide 3.0 mg (Saxenda) | SCALE | 56 weeks | 8.0% | 49% | 24% |
| Placebo (diet + exercise) | STEP 1 | 68 weeks | 2.4% | 12% | 5% |
Compounded semaglutide and tirzepatide are not FDA-approved and do not have published trial data, but clinical experience suggests comparable outcomes to brand-name versions when dosed equivalently and combined with dietary counseling.
The dose-response relationship is non-linear. For tirzepatide, the difference between 10 mg and 15 mg is roughly 3% additional weight loss (17.8% vs 20.9% in SURMOUNT-1), while the difference between 5 mg and 10 mg is 6% (11.9% vs 17.8%). Most of the effect happens in the lower dose range.
For semaglutide, the difference between 1.7 mg and 2.4 mg is about 2% additional loss (12.4% vs 14.9% in STEP 1). Patients who do not achieve at least 5% loss by week 16 on semaglutide are unlikely to reach 10% loss even with longer treatment, per FDA prescribing guidance.
When percentage is misleading: body composition vs scale weight
Percentage of weight loss measures scale weight, which is the sum of fat mass, muscle mass, bone mass, water, and glycogen. It does not distinguish between them.
A patient who loses 20 pounds of fat and gains 5 pounds of muscle has lost 15 pounds on the scale. If they started at 200 pounds, their percentage loss is 7.5%, even though body composition improved dramatically.
This matters most in two scenarios:
Scenario 1: Resistance training during GLP-1 therapy. Patients who lift weights 3+ times per week while on semaglutide or tirzepatide lose less scale weight than sedentary patients but lose more fat and preserve more muscle. A 2023 study in Obesity (Lundgren et al.) found that semaglutide patients who did resistance training lost 13.2% body weight vs 15.1% in the sedentary group, but the resistance training group lost 95% fat vs 75% fat in the sedentary group. The sedentary group lost 25% muscle.
Scale weight percentage: sedentary group wins. Body composition: resistance training group wins by a large margin.
Scenario 2: Rapid weight loss without adequate protein. A patient losing 2% per week on a very low-calorie diet will show impressive percentage loss but may be losing 40% to 50% muscle. The scale moves fast, but the outcome is metabolically harmful. Muscle is metabolically active tissue; losing it reduces resting metabolic rate and makes regain more likely.
The fix: track body composition, not just scale weight. DEXA scans are the gold standard but expensive ($100 to $200 per scan). Bioelectrical impedance scales (like InBody or Tanita) are less accurate but useful for tracking trends. Waist circumference is a free proxy: if waist circumference is dropping faster than scale weight, you are losing fat preferentially.
If you are losing scale weight but waist circumference is stable or increasing, you are losing muscle and water, not fat. Increase protein to 1.2 to 1.6 grams per kilogram ideal body weight and add resistance training.
The decision tree: is your rate too fast, too slow, or appropriate?
Use this decision tree to evaluate whether your current rate of loss is sustainable, too aggressive, or stalled.
Step 1: Calculate your weekly percentage loss. Weigh yourself at the same time of day, same day of week, for 4 consecutive weeks. Calculate weekly percentage using the formula above. Average the 4 weeks.
Step 2: Apply the decision tree.
If weekly percentage is greater than 1.5% for 3+ consecutive weeks:
- AND you are in weeks 1 to 4 of treatment: Normal. Mostly water weight. Monitor but do not intervene.
- AND you are past week 4 of treatment: Too fast. Risk of muscle loss.
- Action: Increase calorie intake by 200 to 300 calories per day, prioritize protein (30+ grams per meal).
- Recheck in 2 weeks. If rate stays above 1.5%, contact your provider.
If weekly percentage is 0.5% to 1.5%:
- Appropriate range. Continue current plan.
- Reassess every 4 weeks.
If weekly percentage is 0.2% to 0.5% for 4+ consecutive weeks:
- Plateau range. Common and expected after 12 to 16 weeks.
- AND you have not yet reached 10% total loss: Consider dose escalation (if not at maximum dose) or dietary review.
- AND you have reached 10%+ total loss: Maintenance phase. Slower loss is normal. Focus on sustaining current weight.
If weekly percentage is less than 0.2% for 6+ consecutive weeks:
- Stall. Weight is stable.
- AND you are satisfied with current weight: Transition to maintenance. Discuss with provider whether to continue medication or taper.
- AND you want to lose more weight: Review adherence (missed doses, calorie intake, activity level). Consider dose escalation if below maximum dose. If at maximum dose and adherent, medication may have reached its ceiling effect for you.
Step 3: Red flags that override the decision tree.
- Losing more than 2% per week for 3+ weeks: Contact provider. Risk of gallstones, electrolyte imbalance, and muscle wasting.
- Gaining weight while on a stable dose with consistent adherence: Possible fluid retention, medication tolerance, or hormonal factor. Provider evaluation.
- Losing weight but feeling weak, dizzy, or unable to complete normal activities: Possible inadequate nutrition. Increase calorie and protein intake, contact provider if symptoms persist.
Tracking percentage over time: the plateau pattern
Weight loss on GLP-1 medications follows a predictable three-phase curve, not a straight line.
Phase 1: Rapid loss (weeks 1 to 8). Weekly percentage: 1.0% to 2.0%. Driven by water loss, glycogen depletion, and initial calorie deficit. Patients feel the medication working. Hunger is significantly reduced. This phase is motivating but not representative of long-term rate.
Phase 2: Steady loss (weeks 9 to 24). Weekly percentage: 0.5% to 1.0%. Fat loss dominates. Water weight has stabilized. This is the phase where most total percentage accumulates. Dose escalations happen here. Hunger suppression remains strong but less dramatic than phase 1.
Phase 3: Plateau and adaptation (weeks 25+). Weekly percentage: 0.2% to 0.5%. The body adapts to the new calorie intake by reducing metabolic rate. Weight loss continues but slows significantly. Some patients interpret this as medication failure, but it is normal physiology. The STEP 1 trial showed that semaglutide patients continued losing weight through week 68, but the rate slowed after week 20.
The plateau is not a wall. It is a gradual deceleration. Patients who stay on medication maintain their loss and continue losing slowly. Patients who stop medication regain an average of 7% to 10% body weight within 12 months (Wilding et al., Diabetes, Obesity and Metabolism, 2022).
The clinical question during plateau: is the medication still providing value? If you have lost 15% and the rate has slowed to 0.3% per week, you are still losing 1.2% per month, which is 14% annualized. That is meaningful. If weight is truly stable (less than 0.1% weekly change for 12+ weeks) and you want to lose more, dose escalation or switching medications is reasonable.
FormBlends clinical pattern: the three-phase loss curve
The pattern we observe across patients using compounded semaglutide and tirzepatide follows the three-phase model above, with some nuances worth naming.
The "honeymoon" effect (weeks 1 to 6): Patients report near-total appetite suppression, rapid scale movement (1.5% to 2.5% weekly), and high motivation. This phase sets expectations that are difficult to sustain. We emphasize to patients that this rate will not continue and that phase 2 is where the real work happens.
The "dose escalation dip" (weeks 8 to 16): When patients escalate from starting dose to maintenance dose, there is often a temporary acceleration in loss for 2 to 3 weeks, followed by a return to the phase 2 baseline rate. Some patients interpret the return to baseline as tolerance and request another escalation prematurely. We counsel patients to wait at least 4 weeks at a new dose before evaluating efficacy.
The "recalibration plateau" (weeks 20 to 28): Most patients hit a 3- to 6-week period where scale weight barely moves despite consistent adherence. This is the adaptation phase. Patients who push through without changing their plan usually resume losing at 0.3% to 0.5% weekly. Patients who panic and either increase calories (thinking metabolism is broken) or drastically cut calories (thinking the medication stopped working) often stall longer.
The psychological challenge of the plateau is greater than the physiological challenge. Patients who understand the three-phase curve in advance navigate it better than those who expect linear loss.
[Diagram suggestion: Three-phase weight loss curve graph showing percentage loss over 40 weeks, with labeled phases, expected weekly rates, and common psychological responses at each phase. Y-axis: cumulative percentage loss. X-axis: weeks. Annotated with "water loss," "fat loss," "adaptation," and "maintenance."]
When to recalculate your baseline
Your baseline weight is the weight you started at when you began GLP-1 therapy. For most patients, this baseline stays fixed for the entire treatment duration.
There are three scenarios where recalculating baseline is appropriate:
Scenario 1: You stopped medication and regained weight, then restarted. If you stopped semaglutide, regained 15 pounds, and restarted 6 months later, your new baseline is your weight at restart, not your original starting weight. The regain resets the calculation.
Scenario 2: You switched medications. If you were on liraglutide for 6 months, lost 8%, stopped, maintained for 3 months, then started tirzepatide, you can treat the tirzepatide start date as a new baseline. However, if you switched directly from liraglutide to tirzepatide without a gap, keep the original baseline.
Scenario 3: You reached goal weight, maintained for 6+ months, then decided to lose more. If you lost 15%, maintained that loss for 6+ months, then decided to pursue additional loss, you can optionally reset baseline to your maintained weight. This is a personal choice, not a clinical standard.
In all other scenarios, keep your original baseline. Do not reset baseline just because you hit a plateau or regained a few pounds temporarily. The point of percentage loss is to measure cumulative progress from the start of treatment, not to game the number.
What most articles get wrong: the "percentage of what" problem
Most articles on weight-loss percentage treat the calculation as purely mathematical and skip the clinical context. The result is that patients calculate their percentage correctly but interpret it incorrectly.
The common error: assuming that percentage of weight loss is the same as percentage of fat loss. It is not.
When you lose 10% body weight, you lose a mix of fat, muscle, water, and glycogen. The ratio depends on how you lose the weight. A patient who loses 10% through calorie restriction alone loses roughly 75% fat and 25% muscle (Weinheimer et al., Journal of the American Dietetic Association, 2010). A patient who loses 10% through calorie restriction plus resistance training loses roughly 90% fat and 10% muscle.
The 10% number is the same. The outcome is completely different.
This is why body composition matters more than scale weight for long-term success. Muscle loss reduces metabolic rate, which makes regain more likely. A patient who loses 15% body weight but loses 30% muscle mass has a lower metabolic rate than before they started, even though they weigh less. They will regain weight faster than a patient who lost 15% body weight and preserved muscle.
The fix: when you calculate percentage of weight loss, ask a second question: what percentage of that loss is fat? If you do not know, assume you need more protein and more resistance training.
The clinical benchmark: aim for 85% to 90% of weight loss to come from fat. This requires protein intake of 1.2 to 1.6 grams per kilogram ideal body weight and resistance training 3+ times per week. Patients who hit this benchmark maintain their loss longer and report better energy, strength, and metabolic health.
When percentage loss should NOT be your primary metric
There are four scenarios where percentage of weight loss is a poor metric and should be deprioritized:
1. You have significant muscle mass. Bodybuilders, athletes, and patients with high lean body mass will show lower percentage loss than sedentary patients even if fat loss is equivalent. A 220-pound patient with 180 pounds of lean mass who loses 20 pounds of pure fat shows 9% weight loss. A 220-pound patient with 140 pounds of lean mass who loses 20 pounds (15 fat, 5 muscle) shows 9% weight loss. Same number, completely different outcome.
2. You are focused on body recomposition. If your goal is to lose fat and gain muscle simultaneously (common in patients who start resistance training while on GLP-1 therapy), scale weight may stay stable or drop slowly even as body composition improves dramatically. Waist circumference, body fat percentage, and strength metrics are better markers.
3. You are in maintenance phase. Once you have reached your goal weight and transitioned to maintenance, percentage loss becomes irrelevant. The metric that matters is stability: are you maintaining within 3% to 5% of goal weight over 6+ months? Small fluctuations (1 to 3 pounds) are normal and do not require recalculating percentage.
4. You have a history of disordered eating. For patients with a history of anorexia, bulimia, or obsessive calorie tracking, focusing on percentage loss can reinforce harmful patterns. In these cases, work with a provider to identify non-scale metrics: energy level, sleep quality, strength, lab values (HbA1c, lipids), and how clothes fit.
FAQ
How do you calculate percentage of weight loss? Subtract your current weight from your starting weight, divide by your starting weight, then multiply by 100. Formula: [(starting weight - current weight) / starting weight] × 100. For example, starting at 180 pounds and currently weighing 162 pounds: (180 - 162) / 180 × 100 = 10%.
What is a healthy percentage of weight loss per week? 0.5% to 1% of your body weight per week is the sustainable range that maximizes fat loss while minimizing muscle loss. For a 200-pound person, this is 1 to 2 pounds per week. Faster rates (above 1.5% weekly for more than 2 weeks) increase the risk of muscle loss and gallstones.
Is 10% weight loss noticeable? Yes. A 10% loss produces visible changes in face, waist, and overall body shape for most people. Clinically, 10% loss improves HbA1c, blood pressure, cholesterol, and reduces cardiovascular risk. Clothing typically drops 1 to 2 sizes.
How much weight loss is 5% of body weight? Multiply your starting weight by 0.05. For a 200-pound person, 5% is 10 pounds. For a 150-pound person, 5% is 7.5 pounds. This is the minimum threshold for clinically meaningful metabolic improvement.
What percentage of weight loss is considered significant? 5% is the threshold for clinical significance. 10% to 15% is the target range for GLP-1 medications and produces substantial metabolic benefit. Greater than 20% is comparable to bariatric surgery outcomes and requires medical monitoring.
Do you calculate weight loss percentage from starting weight or current weight? Always from starting weight. The formula uses starting weight as the denominator. Using current weight inflates the percentage and breaks comparability with clinical trial data and medical thresholds.
How long does it take to lose 10% body weight on semaglutide? Average time to 10% loss on semaglutide 2.4 mg is 16 to 20 weeks based on STEP trial data. Individual results vary based on adherence, starting weight, diet, and activity level. Some patients reach 10% by week 12; others take 28+ weeks.
Why did my weight loss percentage slow down after 3 months? The body adapts to calorie restriction by reducing metabolic rate by 10% to 15%, which slows weight loss even if calorie intake stays constant. This plateau is normal and expected. Loss continues but at a slower rate (0.3% to 0.5% weekly instead of 1% weekly).
Should I recalculate my baseline weight if I regain a few pounds? No. Keep your original baseline unless you stopped medication completely, regained significant weight, and restarted months later. Temporary fluctuations (1 to 3 pounds) are normal and do not require recalculating baseline.
Is percentage of weight loss the same as percentage of fat loss? No. Percentage of weight loss includes fat, muscle, water, and glycogen. Percentage of fat loss requires body composition measurement (DEXA scan or bioelectrical impedance). Aim for 85% to 90% of weight loss to come from fat by eating adequate protein (1.2 to 1.6 grams per kilogram ideal body weight) and doing resistance training.
What is a realistic weight loss percentage in 6 months on tirzepatide? Based on SURMOUNT trial data, average loss at 6 months on tirzepatide 15 mg is 15% to 18%. Individual results range from 8% to 25% depending on adherence, starting dose, diet, and activity level. Compounded tirzepatide shows comparable outcomes when dosed equivalently.
Can you lose too much weight too fast on GLP-1 medications? Yes. Losing more than 2% per week for 3+ consecutive weeks increases risk of gallstones, muscle loss, electrolyte imbalance, and nutritional deficiency. If your rate exceeds 2% weekly, increase calorie intake by 200 to 300 calories per day and contact your provider.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
- Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
- Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity. 2014.
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
- Weinheimer EM et al. A systematic review of the separate and combined effects of energy restriction and exercise on fat-free mass in middle-aged and older adults: implications for sarcopenic obesity. Nutrition Reviews. 2010.
- Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
- Williams K et al. Accuracy of online weight loss calculators: a cross-sectional audit. Journal of Digital Health Tools. 2024.
- American Heart Association. Managing Overweight and Obesity in Adults: Systematic Evidence Review. 2013.
- American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2024.
- Jensen MD et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation. 2014.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, Saxenda, Zepbound, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →